# A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

> **NCT01689220** · PHASE1 · COMPLETED · sponsor: **Solasia Pharma K.K.** · enrollment: 6 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** SP-02L (darinaparsin for injection)
- **DRUG:** SP-02L (darinaparsin for injection)

## Key facts

- **NCT ID:** NCT01689220
- **Lead sponsor:** Solasia Pharma K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-01
- **Final completion:** 2014-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01689220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01689220, "A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01689220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*